A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002005
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
To determine the safety profile and maximum tolerated dose (MTD) of recombinant soluble human CD4 (rCD4) therapy in patients with AIDS or AIDS related complex (ARC). To obtain a preliminary indication of the antiviral effects of rCD4 in patients with AIDS and ARC. To measure steady state serum levels of rCD4 following continuous infusion therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Genentech Inc
🇺🇸South San Francisco, California, United States